<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:10:43 -0700</creation_date>
  <update_date>2013-05-27 11:06:13 -0600</update_date>
  <accession>HMDBP03137</accession>
  <secondary_accessions>
    <accession>8686</accession>
    <accession>HMDBP04947</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>CA-IV</synonym>
    <synonym>Carbonate dehydratase IV</synonym>
    <synonym>Carbonic anhydrase IV</synonym>
  </synonyms>
  <gene_name>CA4</gene_name>
  <general_function>Involved in carbonate dehydratase activity</general_function>
  <specific_function>Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
</specific_function>
  <pathways>
    <pathway>
      <name>Proximal tubule bicarbonate reclamation</name>
      <smpdb_id/>
      <kegg_map_id>map04964</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00595</accession>
      <name>Hydrogen carbonate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00588</accession>
      <name>Sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01303</accession>
      <name>Zinc (II) ion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01967</accession>
      <name>Carbon dioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03538</accession>
      <name>Carbonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05034</accession>
      <name>Topiramate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01928</accession>
      <name>Hydrochlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14377</accession>
      <name>Methyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14456</accession>
      <name>Ethoxzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14580</accession>
      <name>Bendroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14702</accession>
      <name>Benzthiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14744</accession>
      <name>Cyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14841</accession>
      <name>Methazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14912</accession>
      <name>Hydroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14957</accession>
      <name>Acetazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15007</accession>
      <name>Dorzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15018</accession>
      <name>Chlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15156</accession>
      <name>Trichlormethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15275</accession>
      <name>Dichlorphenamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15325</accession>
      <name>Brinzolamide</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbon-oxygen lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydro-lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbonate dehydratase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>one-carbon metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>anchored to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>plasma membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>anchored to external side of plasma membrane</description>
      <go_id>GO:0031362</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>apical plasma membrane</description>
      <go_id>GO:0016324</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>brush border membrane</description>
      <go_id>GO:0031526</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum-Golgi intermediate compartment</description>
      <go_id>GO:0005793</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>Golgi apparatus</description>
      <go_id>GO:0005794</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>perinuclear region of cytoplasm</description>
      <go_id>GO:0048471</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>rough endoplasmic reticulum</description>
      <go_id>GO:0005791</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>sarcolemma</description>
      <go_id>GO:0042383</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>sarcoplasmic reticulum</description>
      <go_id>GO:0016529</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>secretory granule membrane</description>
      <go_id>GO:0030667</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>trans-Golgi network</description>
      <go_id>GO:0005802</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>transport vesicle membrane</description>
      <go_id>GO:0030658</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>carbonate dehydratase activity</description>
      <go_id>GO:0004089</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>zinc ion binding</description>
      <go_id>GO:0008270</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bicarbonate transport</description>
      <go_id>GO:0015701</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>one-carbon metabolic process</description>
      <go_id>GO:0006730</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>organ development</description>
      <go_id>GO:0048513</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to steroid hormone stimulus</description>
      <go_id>GO:0048545</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Lipid-anchor</subcellular_location>
    <subcellular_location>GPI-anchor</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>17</chromosome_location>
    <locus>17q23</locus>
    <gene_sequence>&gt;939 bp
ATGCGGATGCTGCTGGCGCTCCTGGCCCTCTCCGCGGCGCGGCCATCGGCCAGTGCAGAG
TCACACTGGTGCTACGAGGTTCAAGCCGAGTCCTCCAACTACCCCTGCTTGGTGCCAGTC
AAGTGGGGTGGAAACTGCCAGAAGGACCGCCAGTCCCCCATCAACATCGTCACCACCAAG
GCAAAGGTGGACAAAAAACTGGGACGCTTCTTCTTCTCTGGCTACGATAAGAAGCAAACG
TGGACTGTCCAAAATAACGGGCACTCAGTGATGATGTTGCTGGAGAACAAGGCCAGCATT
TCTGGAGGAGGACTGCCTGCCCCATACCAGGCCAAACAGTTGCACCTGCACTGGTCCGAC
TTGCCATATAAGGGCTCGGAGCACAGCCTCGATGGGGAGCACTTTGCCATGGAGATGCAC
ATAGTACATGAGAAAGAGAAGGGGACATCGAGGAATGTGAAAGAGGCCCAGGACCCTGAA
GACGAAATTGCGGTGCTGGCCTTTCTGGTGGAGGCTGGAACCCAGGTGAACGAGGGCTTC
CAGCCACTGGTGGAGGCACTGTCTAATATCCCCAAACCTGAGATGAGCACTACGATGGCA
GAGAGCAGCCTGTTGGACCTGCTCCCCAAGGAGGAGAAACTGAGGCACTACTTCCGCTAC
CTGGGCTCACTCACCACACCGACCTGCGATGAGAAGGTCGTCTGGACTGTGTTCCGGGAG
CCCATTCAGCTTCACAGAGAACAGATCCTGGCATTCTCTCAGAAGCTGTACTACGACAAG
GAACAGACAGTGAGCATGAAGGACAATGTCAGGCCCCTGCAGCAGCTGGGGCAGCGCACG
GTGATAAAGTCCGGGGCCCCGGGTCGGCCGCTGCCCTGGGCCCTGCCTGCCCTGCTGGGC
CCCATGCTGGCCTGCCTGCTGGCCGGCTTCCTGCGATGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>312</residue_number>
    <molecular_weight>35032.075</molecular_weight>
    <theoretical_pi>7.821</theoretical_pi>
    <pfams>
      <pfam>
        <name>Carb_anhydrase</name>
        <pfam_id>PF00194</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Carbonic anhydrase 4
MRMLLALLALSAARPSASAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTK
AKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSD
LPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGF
QPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFRE
PIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKSGAPGRPLPWALPALLG
PMLACLLAGFLR</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P22748</uniprot_id>
  <uniprot_name>CAH4_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1ZNC</pdb_id>
    <pdb_id>3F7B</pdb_id>
    <pdb_id>3F7U</pdb_id>
    <pdb_id>3FW3</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M83670</genbank_gene_id>
  <genecard_id>CA4</genecard_id>
  <geneatlas_id>CA4</geneatlas_id>
  <hgnc_id>HGNC:1375</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Okuyama T, Sato S, Zhu XL, Waheed A, Sly WS: Human carbonic anhydrase IV: cDNA cloning, sequence comparison, and expression in COS cell membranes. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1315-9.</reference_text>
      <pubmed_id>1311094</pubmed_id>
    </reference>
    <reference>
      <reference_text>Okuyama T, Batanian JR, Sly WS: Genomic organization and localization of gene for human carbonic anhydrase IV to chromosome 17q. Genomics. 1993 Jun;16(3):678-84.</reference_text>
      <pubmed_id>8325641</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhu XL, Sly WS: Carbonic anhydrase IV from human lung. Purification, characterization, and comparison with membrane carbonic anhydrase from human kidney. J Biol Chem. 1990 May 25;265(15):8795-801.</reference_text>
      <pubmed_id>2111324</pubmed_id>
    </reference>
    <reference>
      <reference_text>Waheed A, Okuyama T, Heyduk T, Sly WS: Carbonic anhydrase IV: purification of a secretory form of the recombinant human enzyme and identification of the positions and importance of its disulfide bonds. Arch Biochem Biophys. 1996 Sep 15;333(2):432-8.</reference_text>
      <pubmed_id>8809084</pubmed_id>
    </reference>
    <reference>
      <reference_text>Okuyama T, Waheed A, Kusumoto W, Zhu XL, Sly WS: Carbonic anhydrase IV: role of removal of C-terminal domain in glycosylphosphatidylinositol anchoring and realization of enzyme activity. Arch Biochem Biophys. 1995 Jul 10;320(2):315-22.</reference_text>
      <pubmed_id>7625839</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry. 2006 Sep 18;12(27):7057-66.</reference_text>
      <pubmed_id>16807956</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem. 2006 May 18;49(10):3019-27.</reference_text>
      <pubmed_id>16686544</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kohler K, Hillebrecht A, Schulze Wischeler J, Innocenti A, Heine A, Supuran CT, Klebe G: Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl. 2007;46(40):7697-9.</reference_text>
      <pubmed_id>17705204</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett. 2007 Feb 1;17(3):628-35. Epub 2006 Nov 15.</reference_text>
      <pubmed_id>17127057</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Guerri A, Scozzafava A, Rusconi S, Supuran CT: Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2210-5. Epub 2007 Feb 8.</reference_text>
      <pubmed_id>17314045</pubmed_id>
    </reference>
    <reference>
      <reference_text>Crocetti L, Maresca A, Temperini C, Hall RA, Scozzafava A, Muhlschlegel FA, Supuran CT: A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1371-5. Epub 2009 Jan 19.</reference_text>
      <pubmed_id>19186056</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT: Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009 Mar 4;131(8):3057-62.</reference_text>
      <pubmed_id>19206230</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G: Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins. 2009 Jan;74(1):164-75.</reference_text>
      <pubmed_id>18618712</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stams T, Nair SK, Okuyama T, Waheed A, Sly WS, Christianson DW: Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8-A resolution. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13589-94.</reference_text>
      <pubmed_id>8942978</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yang Z, Alvarez BV, Chakarova C, Jiang L, Karan G, Frederick JM, Zhao Y, Sauve Y, Li X, Zrenner E, Wissinger B, Hollander AI, Katz B, Baehr W, Cremers FP, Casey JR, Bhattacharya SS, Zhang K: Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal photoreceptor degeneration. Hum Mol Genet. 2005 Jan 15;14(2):255-65. Epub 2004 Nov 24.</reference_text>
      <pubmed_id>15563508</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.</reference_text>
        <pubmed_id>10713865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Avvaru BS, Wagner JM, Maresca A, Scozzafava A, Robbins AH, Supuran CT, McKenna R: Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. Epub 2010 Jun 17.</reference_text>
        <pubmed_id>20605094</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76.</reference_text>
        <pubmed_id>8875343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.</reference_text>
        <pubmed_id>10713865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases.  Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36.</reference_text>
        <pubmed_id>10954127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21.</reference_text>
        <pubmed_id>19703035</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.  Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92.</reference_text>
        <pubmed_id>18537527</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders.  Mini Rev Med Chem. 2008 Sep;8(10):968-75.</reference_text>
        <pubmed_id>18782051</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Biton V: Clinical pharmacology and mechanism of action of zonisamide.  Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40.</reference_text>
        <pubmed_id>17762320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Zonisamide: new drug. No advantage in refractory partial epilepsy.  Prescrire Int. 2007 Jun;16(89):95-7.</reference_text>
        <pubmed_id>17582922</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9.</reference_text>
        <pubmed_id>14971907</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
